Miederer M - Search Results

1

Targeted actinium-225 in vivo generators for therapy of ovarian cancer.

Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Borchardt PE, et al. Among authors: miederer m. Cancer Res. 2003 Aug 15;63(16):5084-90. Cancer Res. 2003. PMID: 12941838

2

Highly specific tumor binding of a 213Bi-labeled monoclonal antibody against mutant E-cadherin suggests its usefulness for locoregional alpha-radioimmunotherapy of diffuse-type gastric cancer.

Senekowitsch-Schmidtke R, Schuhmacher C, Becker KF, Nikula TK, Seidl C, Becker I, Miederer M, Apostolidis C, Adam C, Huber R, Kremmer E, Fischer K, Schwaiger M. Senekowitsch-Schmidtke R, et al. Among authors: miederer m. Cancer Res. 2001 Apr 1;61(7):2804-8. Cancer Res. 2001. PMID: 11306447

3

Tumor therapy with targeted atomic nanogenerators.

McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. McDevitt MR, et al. Among authors: miederer m. Science. 2001 Nov 16;294(5546):1537-40. doi: 10.1126/science.1064126. Science. 2001. PMID: 11711678

4

Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.

Miederer M, McDevitt MR, Sgouros G, Kramer K, Cheung NK, Scheinberg DA. Miederer M, et al. J Nucl Med. 2004 Jan;45(1):129-37. J Nucl Med. 2004. PMID: 14734685 Free article.

5

Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2.

Miederer M, McDevitt MR, Borchardt P, Bergman I, Kramer K, Cheung NK, Scheinberg DA. Miederer M, et al. Clin Cancer Res. 2004 Oct 15;10(20):6985-92. doi: 10.1158/1078-0432.CCR-04-0859. Clin Cancer Res. 2004. PMID: 15501978

6

Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Miederer M, Scheinberg DA, McDevitt MR. Miederer M, et al. Adv Drug Deliv Rev. 2008 Sep;60(12):1371-82. doi: 10.1016/j.addr.2008.04.009. Epub 2008 Apr 23. Adv Drug Deliv Rev. 2008. PMID: 18514364 Free PMC article. Review.

7

Alpha-Emitting Radionuclides: Current Status and Future Perspectives.

Miederer M, Benešová-Schäfer M, Mamat C, Kästner D, Pretze M, Michler E, Brogsitter C, Kotzerke J, Kopka K, Scheinberg DA, McDevitt MR. Miederer M, et al. Pharmaceuticals (Basel). 2024 Jan 8;17(1):76. doi: 10.3390/ph17010076. Pharmaceuticals (Basel). 2024. PMID: 38256909 Free PMC article. Review.

8

Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using 149Tb-rituximab.

Beyer GJ, Miederer M, Vranjes-Durić S, Comor JJ, Künzi G, Hartley O, Senekowitsch-Schmidtke R, Soloviev D, Buchegger F. Beyer GJ, et al. Among authors: miederer m. Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):547-54. doi: 10.1007/s00259-003-1413-9. Epub 2004 Jan 14. Eur J Nucl Med Mol Imaging. 2004. PMID: 14722680

9

In vivo Evaluation of [²²⁵Ac]Ac-DOTA^ZOL for α-Therapy of Bone Metastases.

Pfannkuchen N, Bausbacher N, Pektor S, Miederer M, Rosch F. Pfannkuchen N, et al. Among authors: miederer m. Curr Radiopharm. 2018;11(3):223-230. doi: 10.2174/1874471011666180604083911. Curr Radiopharm. 2018. PMID: 29866026

10

Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein.

Miederer M, Seidl C, Beyer GJ, Charlton DE, Vranjes-Duric S, Comor JJ, Huber R, Nikula T, Apostolidis C, Schuhmacher C, Becker KF, Senekowitsch-Schmidtke R. Miederer M, et al. Radiat Res. 2003 May;159(5):612-20. doi: 10.1667/0033-7587(2003)159[0612:cotrot]2.0.co;2. Radiat Res. 2003. PMID: 12710872

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters